Eli Lilly is advancing glucose control to target systemic complications like heart disease, kidney disease, and sleep apnea. Their dual-agonist, tirzepatide, known as Mounjaro or Zepbound, provides significant cardio and renoprotective benefits while driving the substantial weight loss necessary to reduce metabolic strain. This matters because it is the first medication approved to treat obstructive sleep apnea, addressing the metabolic triad of the heart, kidneys, and respiratory system. By tackling these interconnected issues, Lilly offers a comprehensive strategy for long-term health that goes far beyond just managing a single A1C number.